Rabies is a virtually 100% fatal acute viral encephalitis, caused by the RNA virus Rhabdovirus (genus Lyssavirus), which infects central nervous system tissue and salivary glands. The virus can infect all warm-blooded animals; the disease is transmitted to humans by the bite/lick/ scratch of an infected animal.
Rabies is a virtually 100% fatal acute viral encephalitis, caused by the RNA virus Rhabdovirus (genus Lyssavirus), which infects central nervous system tissue and salivary glands. The virus can infect all warm-blooded animals; the disease is transmitted to humans by the bite/lick/ scratch of an infected animal. 1 Rabies
Intra-dermal administration of rabies vaccines in developing countries
At an affordable cost occurs in more than 150 countries and territories. 2 Annually, there are 17.4 million animal bite cases and more than 55,000 people die of rabies globally. 40% of people who are bitten by suspect rabid animals are children under 15 years of age; the majority are male. Every year, more than 15 million people worldwide receive a post-exposure preventive regimen to avert the disease-this is estimated to prevent 327,000 rabies deaths annually. Dogs are the source of 99% of human rabies deaths. 2 India accounts for 36% of the Global (55,000) and 65% of Asian (31,000) deaths due to rabies i.e., 20,000 rabies deaths (i.e., about 2/100,000 population at risk) are estimated to occur annually. 3 This corresponds to frequencies of animal bites of once every two seconds and a rabies death once every 30 min. 3 In India, rabies has been reported from all states except Lakshadweep and the Andaman and Nicobar Islands. 4 The disease is virtually 100% fatal but can be rendered virtually 100% preventable. 5 Wound cleansing and immunization within a few hours after contact with a suspect rabid animal can prevent the onset of rabies and death. 6 In India, nervous tissue vaccines (NTV) used to be the most frequently used vaccines for anti-rabies treatment; now this being replaced by modern, safe and effective cell culture vaccines (CCVs) due to NTV's inherent neuroparalytic side-effects. But high cost and limited availability have been the limiting factors for the wider use of CCVs, 7 which is administered intramuscularly (IM).
The Intradermal Rabies Vaccine (IDRV) project was first started in ©2 0 1 1 L a n d e s B i o s c i e n c e .
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Commentary Commentary preservative should be used within 6-8 h if kept at 2-8°C. All reconstituted vaccine that is unused at the end of 6-8 h must be discarded.
Although some authors have shown the efficacy of the vaccine even after more than 24 h following reconstitution, but for practical purposes it should be used between 4-6 h. 13, 14 As per Drug Controller General of India (DCGI) guidelines, the intradermal rabies vaccines should be given in the antirabies clinics where minimum of 50 animal bite cases report daily. 3 The best combination of disposable syringe and needle for IDRV is the insulin syringe with attached needle (26G). Each insulin syringe has a mark of 40 units, which is equivalent to a 1 mL volume. So for four units, the volume becomes 0.1 mL. Therefore, eight units of the vaccine are in a 0.2 ml volume, whereas 0.1 mL (four units) are injected ID per vaccination site. Preferably separate syringe and needles are use for each vaccine, and adequate biomedical waste management measures must be adhered too.
The full course of vaccination in the IM regimen is five visits with five doses or five vials, while for the ID regimen it is 0.2 ml x four visits (0.8 mL) ( Table 1) .
The ID route is ideal in terms of economic benefits, safety and efficacy. It reduces the cost of vaccination by about 68%, which is clearly an attractive option for resource-starved countries like India. 15 By this technique, we are able to reduce the indirect cost involved in terms of manhour cost, travel time and expenses for that visit. Vaccine shortage is a problem in our clinic and also in most Government hospitals, and most of those who come for treatment cannot afford to buy the complete schedule of vaccines, since the cost of each dose ranges from Rs. 280 to Rs. 300. Data from preventive clinics is needed for each patient, resulting in the use of ≈1 vial/patient considering wastage factor of vaccine 20% as opposed to five vials/patient that receive PEP using the IM route.
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Method of Administration
One dose of vaccine in a volume of 0.1 mL is to be injected through the intradermal route. The skin first is made sterile and the site of administration is stretched. The needle with its beveled-end facing upward should be pierced in the stretched skin up to 5 mm. Then the vaccine is slowly injected. A perfect ID administration will lead to the formation of an elevated wheal of about 5 mm in diameter with peau-deorange appearance, i.e., a visible and palpable "bleb" in the skin. The usual sites of administration are on two different lymphatic drainage sites (usually the left and right upper arm, i.e., deltoid region of each arm). In the event that a dose of vaccine is inadvertently given subcutaneous (SC) or IM, a new dose should be administered ID at nearby side. If a dose is given (SC), then there is a possibility of a poor immune response due to low antigenic load. 12 Maintenance of the cold chain is of utmost importance to ensure that potency of rabies vaccine is retained. If great care is taken with aseptic technique, an appropriate dose of vaccine may be withdrawn from a vial and the remainder used for another patient, provided that the vial is stored in a refrigerator at 2-8°C. A sterile needle and syringe must be used to draw up vaccine for each patient to prevent cross-infection of hepatitis, HIV and other infections. Although the vaccine antigen is very stable at 4°C, there is a high risk of contamination of multi-dose vials by microorganisms, especially if the vaccine does not contain a preservative. Reconstituted vaccines should be used as soon as possible, and those vials without 
Sites and Dose for Intradermal Regimen
The regimen approved by the WHO/ DCGI India is the Updated Thai Red Cross Regimen involving injection of 0.1 mL of reconstituted vaccine per each of two ID sites per visit on days 0, 3, 7 and 28 (2-2-2-0-2). Day 0 is the day of first dose administration of IDRV, and may not be the day of animal bite. In this regimen, only four visits are needed for complete vaccination. Day 14 is skipped as compared to the IM regimen. 10 So by this scheme, we are able to reduce the indirect cost involved in terms of man-hour cost, travel time and expenses per visit. In case of a bite site on the arm, the vaccine can be given by the ID route on either thigh or on supra-scapular areas. 8 Dose and age group-0.1 mL (four units of an insulin syringe) on each ID site in all age groups. Since theoretically only 0.8 mL of vaccine ©2 0 1 1 L a n d e s B i o s c i e n c e .
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show that patients attending the clinic and Antirabies Vaccine (ARV) used is increasing year by year, adding a financial burden for the purchase of ARVs. To address these issues where vaccine and money are in short supply, the ID route is ideal in terms of economic benefits, safety and efficacy.
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WHO Views?
WHO promotes wider access to appropriate post-exposure treatment using modern tissue culture or avian embryo-derived rabies vaccines through?
• Use of the multi-site ID regimen to reduce the cost of post-exposure treatments;
• Increased production of safe and efficacious rabies vaccines, which are in critical short supply globally;
• Continuing education of health and veterinary professionals in rabies prevention and control; and
• Immunization of 70% of the dog population to stop circulation of the virus at the source. 
